ATM
ATM is a key gene involved in DNA damage response and repair. Pathogenic alterations may confer sensitivity to DNA-damaging agents and PARP inhibitors and are relevant in multiple solid and hematologic malignancies.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where ATM is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Metastatic Castrate Resistant Prostate Cancer (mCRPC) Solid Tumor · Prostate |
|
Approvals defined at the solid tumor level where ATM is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report ATM as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports ATM as part of its biomarker panel.